1) Strickland L, Letson GD, Muro-Cacho CA. Gastrointestinal stromal tumors. Cancer Control. 8, 252-261, 2001. 2) Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 30, 1213-1220, 1999. 3) Pidhorecky I, Cheney RT, Kraybill WG, et al. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann.Surg.Oncol. 7, 705-712, 2000. 4) Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol. Histopathol. 15, 1293-1301, 2000. 5) Chan JKC..Mesenchymal tumors of the gastrointestinal tract: a paradise for acronyms (STUMP, GIST, GANT, and now GIPACT). Implications of the c-kit in genesis, and yet another of many emerging roles of the intersticial cell of Cajal in the pathogenesis of gastrintestinal disease. Adv.Anat.Pathol. 6, 19-40, 1996. 6) Kindblom I-G., Remotti H., Aldenborg F., et al.. Gastrointestinal pacemaker cell tumor (GIPACT). Gastrointestinal stromal tumors show phenotypic characteristics of the intersticial cells of Cajal. Am.J.Clin.Pathol. 152, 1259-1269, 1998. 7) Sircar K., Hewlett BR., Huizinga JD., et al.. Intersticial cells of Cajal as precursors of gastrointestinal stromal tumors. Am.J. Surg.Pathol. 23, 377-389, 1999. 8) Wang L, Vargas H, French SW. Cellular origin of gastrointestinal stromal tumors: a study of 27 cases. Arch Pathol Lab Med. 124, 1471-1475, 2000. 9) Sakurai S., Fukasawa T., Chong JM., et al.. C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of intersticial cell of Cajal). Jpn.J.Cancer Res. 90, 1321-1328, 1999. 10) Hagger R., Finlayson C., Jeffrey I., et al.. Role of the intersticial cells of Cajal in the control of gut motility. Br.J.Surg. 84, 445-450, 1997. 11) Miettinen M., Sarlomo-Rikala M., Lasota J.. Gastrointestinal stromal tumours. Ann.Chir.Gyn. 87, 278-281, 1998. 12) Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemi- cal, and molecular genetic features and differential diagnosis. Virchows Arch. 438,1-12, 2001. 13) Hjermsted BM., Sobin LH., Helwig EB.. Stromal tumors of the gastrointestinal tract: myogenic or neurogenic?. Am.J.Surg.Pathol. 11, 383-386, 1987. 14) Suster S. Gastrointestinal stromal tumors. Semin.Diagn.Pathol. 13, 297-313, 1996. 15) Graadt van Roggent JF., van Velthuysen MLF., Hogendoorn PCW.. The histopathological differential diagnosis of gastrointestinal stromal tumours. J.Clin.Pathol. 54, 96-103, 2001. 16) Campbell F., Bogomoletz WV., Williams GT.. Non-epithelial tumors: gastric stromal tumors (leiomyoma, leioimyosarcoma, leiomyoblastoma, neurilemmoma, schwannoma, neurofibroma). In: Fletcher Ch.(ed.). Diagnostic Histopathology of Tumors. 2nd. ed., Churchill Livingstone, London, 2.000. pp: 344-347. 17) Owen DA. Stromals tumors. In: Sternberg S.(ed.). Diagnostic Surgical Pathology, 3rd. ed., Lippincott Williams & Wilkins, Philadelphia, 1999. pp: 1337-1339. 18) Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 33, 459-465, 2002. 19) Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279, 577-580, 1998. 20) Lamme A., Drobjnak M., Gerald W., et al.. Expression of c-kit and c-kit ligand proteins in normal human tissues. J.Histochem.Cytochem. 42, 1417-1425, 1994. 21) Matsuda R., Takahashi T., Nakamura S., Sekido Y., Nishida K., Seto M., Seito T., Sugiura T., Ariyoshi Y., Takahashi T., and Ueda R.. Expression of c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am.J.Pathol. 142, 339-346, 1993. 22) Sandlow JI., Feng HL., Sandra A.. Localization and expression of the c-kit receptor protein in human and rodent testis and sperm. Urology 49, 494-500, 1997. 23) Geissler EN., Ryan MA., Housman DE.. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 7, 185-192, 1988. 24) Chabot B., Stephenson DA., Chapman VM., et al.. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335, 88-89, 1988. 25) Vliagrofis H., Worobec AS., Metcalfe DD.. The proto-oncogene c-kit and the c-kit ligand in human disease. J:Allergy.Clin.Immunol. 100, 435-440, 1997. 26) Yarden y., Kuang W., Yang-Feng T., Coussens L., Munemitsu S., Dull J.T., Chen E., Schelessinger J., Francke U., and Ullrich A.. Human proto-oncogen c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO.J. 6, 3341-3351, 1987. 27) Taylor ML, Metcalfe DD. Kit signal transduction. Hematol Oncol Clin North Am. 14, 517-535, 2000. 28) Fina L., Molgaard H.V., Robertson D. et al.. Expression of the CD-34 gene in vascular endothelial cells. Blood. 75, 2417-2426, 1990. 29) Miettinen M. et al.. KIT expression in angiosarcomas and fetal endothelial cells : lack of mutations of exon 11 and exon 17 of C-kit. Mod.Pathol. 13(5), 536-541, 2000. 30) El-Rifai W, Sarlomo-Rikala M, Andersson LC, et al. DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res. 60, 3899-3903, 2000.slide 15]The Genetics of GISTs1 31) Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal solid tumors. Cancer Res. 59, 4297-4300, 1999. 32) Lasota J, Jasinski M, Sarlomo-Rikala M, et al. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am. J. Pathol. 154, 53-60, 1999. 33) Robbins S.. Patología estructural y funcional. 6ª ed., Interamericana, México, 1980. Cp. 21. pp: 871-950. 34) Berman J, O’Leary TJ. Gastrointestinal stromal tumor workshop. Hum.Pathol. 32, 578-582, 2001. 35) Pike AM., Lloyd RV., Appelman HD.. Cell markers in gastrointestinal stromal tumors. Hum.Pathol. 19, 830-834, 1988. 36) Ueyama T., Guo KJ., Hashimoto H., et al.. A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer 69, 947-955, 1992. 37) Hurlimann J., Gardiol D.. Gastrointestinal stromal tumors. An immunohistochemical study of 165 cases. Histopathology 19, 311-320, 1991. 38) Miettinen M.. Gastrointestinal stromal tumors. An immunohistochemical study of cellular differentiation. Am.J. Clin.Pathol. 89, 601-610, 1988. 39) Seidal S. And Edvardsson E..Expression of c-kit (CD117) and Ki-67 provides information of the possible cell of origin and clinical course in gastrointestinal stromal tumors. Histopathol. 34, 416-424, 1999. 40) Sarlomo-Rikala M., Kovatich AJ., Barusevicius A., et al.. CD117: a sensitive marker for gastrintestinal stromal tumors that is more specific than CD34. Mod.Pathol. 11, 728-734, 1998. 41) Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol. 13, 1134-1142, 2000. 42) Tsuura Y., Hiraki H., Watanabe K., Igarashi S., Shimamura K., Fukuda T., Suzuki T., and Seito T.. Preferential localization of c-kit product in tissue mast cell, basal cell of skin, epithelial cells of breast, small cell of lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study of formalin-fixed, paraffin-embedded tissues. Virch.Arch. 424, 135-141, 1994. 43) Arber A. et al.. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum.Pathol. 29(5), 498-504, 1998. 44) Fletcher Ch., and Fletcher J.. Testing for KIT (CD117) in gastrointestinal stromal tumors. A.J.Clin.Pathol. 118 (2), 20-21, 2001. 45) Mikhael AI., Bacchi CE., Zarbo RJ., et al.. CD34 expression in stromal tumors of the gastrointestinal tract. Appl.Immunohistochem. 2, 89-93, 1994. 46) Van de Rijn M., and Rouse R.V.. CD-34, a review. Appl. Immunohistochem. 2(2), 71-80, 1994. 47) Chen C. et al.. CD34, CD117 and actin expression in phyllodes tumor of the breast. J.Surg.Res. 94, (2), 84-91, 2000. 48) Traweek S.T., Kandalaft P.L., Mehta P., and Battifora H.. The human hematopoietic progenitor cell antigen (CD-34) in vascular neoplasia. Am.J.Clin.Pathol. 96, 25-31, 1991. 49) Barrande C., Traore Y., Szekeres G. and Him J.. Isolation and characterization of two new monoclonal antibodies against the CD-34 molecule. Hybridoma 12(2), 203-213, 1993. 50) Reith R. et al.. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors and outcome. Mod.Pathol. 13(5), 577-585, 2000. 51) Weiss, S. and Goldblum, J.. Enzinger and Weiss’s Soft Tissues Tumors. 4a. Ed., Mosby & Co., New York, 2001. Cp. 20, pp: 749-768. 52) Hatch KF, Blanchard DK, Hatch GF, et al. Tumors of the rectum and anal canal. World J Surg. 24, 437-443, 2000. 53) Altmannsberger M., et al.. Desmin is a specific marker for rhabdomyosarcomas of human and rat origin. Amer.J.Pathol. 118, 85, 1985. 54) Miettinen M., et al.. Antibodies to intermediate filament proteins in the diagnosis and classification of human tumors. Ultraestruct.Pathol. 7, 83, 1984. 55) Mill SE., et al.. Leiomyosarcoma of the urinary bladder. A clinicopathologic and immunohistochemical study of 15 cases. Amer.J.Surg.Pathol. 13, 480, 1989. 56) Miettinen M., Virolainen M., Maarit SR.. Gastrointestinal stromal tumors--Value of CD34 antigen in their identification and separation from from true leiomyomas and schwannomas. Am.J.Surg.Pathol. 19, 207-216, 1995. 57) González R., Araya JC., Mandiola S., González J., Urrutia ME.. Aplicación del anticuerpo c-kit (CD117) para diferenciación inmunohistoquímica en tumores estromales gastrointestinales. Rev.Chil.Tecnól.Méd. 22(1), 977-983, 2002. 58) Hibi k., Takahashi T., Sekido Y., Ueda R., Hida T., Ariyoshi Y., Takagi H., and Takahashi T.. Coexpression of stem cell factor and c-kit genes in small-cell lung cancer. Oncogene. 6, 2291-2296, 1991. 59) Emory TS., Sobin LH., Lukes L., et al.. Prognosis of gastrointestinal smooth-muscle (stromal) tumors. Dependence on anatomic site. Am.J.Surg.Pathol. 23, 82-87, 1999. 60) Lasota J. et al.. Spindle cell tumor of urinary bladder serosa with phenotypic and genotypic features of gastrointestinal stromal tumor. Arch.Pathol.Lab.Med. 124(6), 894-897, 2000. 61) Joensuu H.. Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec). Med.Klin. 97, Suppl.1, 28-30, 2002. 62) Heinrich MC.,Blanke CD., Druker BJ., Corless CL.. Inhibition of KIT tirosyne kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J.Clin.Oncol. 20(6), 1692-1703, 2002. 63) Plaat BE, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumours: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol. 18, 3211-3220, 2000. 64) Shioyama Y., Yakeishi Y., Watanabe T., et al.. Long-term control for a retroperitoneal metastasis of malignant gastrointestinal stromal tumor after chemoradiotherapy and immunotherapy. Acta Oncol. 40, 102-104, 2001. 65) DeMatteo R., Heinrich M., El-Rifai W., Demetri G.. Clinical management of Gastrointestinal stromal tumors: before and after STI-571. Hum.Path. 33(5), 466-477, 2002. 66) Berghini B. et al.. Germline mutation in the juxtamembrane domain of the c-kit gene in a family with gastrointestinal stromal tumors and urticuria pigmentosa. Cancer. 92(3), 657-662, 2001.
|